we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
Company profile
Ticker
NVCR
Exchange
Website
CEO
Asaf Danziger
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Novocure Austria GmbH • Novocure Belgium S.r.l. • Novocure Canada, Inc. • Novocure Denmark ApS • NovoCure (Israel) Ltd. • Novocure France SAS • Novocure GmbH • Novocure Inc. • Novocure Italy S.r.L. • Novocure K.K. ...
NVCR stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
27 Mar 24
S-8
Registration of securities for employees
22 Feb 24
8-K
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
22 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
18 Jan 24
8-K
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
9 Jan 24
8-K
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
8 Jan 24
8-K
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
4 Jan 24
8-K
Regulation FD Disclosure
28 Nov 23
8-K
Novocure Reports Third Quarter 2023 Financial Results
26 Oct 23
Transcripts
NVCR
Earnings call transcript
2023 Q4
22 Feb 24
NVCR
Earnings call transcript
2023 Q3
26 Oct 23
NVCR
Earnings call transcript
2023 Q2
27 Jul 23
NVCR
Earnings call transcript
2023 Q1
4 May 23
NVCR
Earnings call transcript
2022 Q4
23 Feb 23
NVCR
Earnings call transcript
2022 Q3
27 Oct 22
NVCR
Earnings call transcript
2022 Q2
28 Jul 22
NVCR
Earnings call transcript
2022 Q1
28 Apr 22
NVCR
Earnings call transcript
2021 Q4
24 Feb 22
NVCR
Earnings call transcript
2021 Q3
28 Oct 21
Latest ownership filings
4
WILHELMUS CM GROENHUYSEN
5 Mar 24
4
Frank X Leonard
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
Ashley Cordova
29 Feb 24
4
Frank X Leonard
29 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 156.51 mm | 156.51 mm | 156.51 mm | 156.51 mm | 156.51 mm | 156.51 mm |
Cash burn (monthly) | 327.33 k | 7.29 mm | 19.42 mm | 18.68 mm | 6.44 mm | 5.21 mm |
Cash used (since last report) | 1.95 mm | 43.48 mm | 115.75 mm | 111.36 mm | 38.38 mm | 31.04 mm |
Cash remaining | 154.56 mm | 113.03 mm | 40.76 mm | 45.16 mm | 118.13 mm | 125.47 mm |
Runway (months of cash) | 472.2 | 15.5 | 2.1 | 2.4 | 18.3 | 24.1 |
Institutional ownership, Q3 2023
85.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 229 |
Opened positions | 45 |
Closed positions | 78 |
Increased positions | 74 |
Reduced positions | 61 |
13F shares | Current |
---|---|
Total value | 1.47 tn |
Total shares | 91.05 mm |
Total puts | 656.90 k |
Total calls | 922.50 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
FMR | 15.96 mm | $257.75 bn |
Vanguard | 9.64 mm | $155.64 bn |
Capital International Investors | 9.00 mm | $145.43 bn |
Capital World Investors | 8.88 mm | $143.39 bn |
BLK Blackrock | 7.86 mm | $126.98 bn |
Baillie Gifford & Co | 6.81 mm | $110.05 bn |
Deep Track Capital | 2.50 mm | $40.38 bn |
T. Rowe Price | 2.36 mm | $38.19 bn |
STT State Street | 2.09 mm | $33.80 bn |
Voloridge Investment Management | 1.71 mm | $27.56 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 24 | Wilhelmus CM Groenhuysen | Ordinary Shares | Sell | Dispose S | No | No | 16.01 | 1,217 | 19.48 k | 251,235 |
4 Mar 24 | Frank X Leonard | Ordinary Shares | Sell | Dispose S | No | No | 16.01 | 840 | 13.45 k | 160,098 |
1 Mar 24 | Wilhelmus CM Groenhuysen | Ordinary Shares | Sell | Dispose S | No | No | 16.0269 | 2,107 | 33.77 k | 252,452 |
1 Mar 24 | Frank X Leonard | Ordinary Shares | Sell | Dispose S | No | No | 16.0269 | 1,679 | 26.91 k | 160,938 |
28 Feb 24 | Frank X Leonard | Ordinary Shares | Sell | Dispose S | No | No | 16.1428 | 2,078 | 33.54 k | 162,617 |
27 Feb 24 | Ashley Cordova | Ordinary Shares | Grant | Acquire A | No | No | 16.3 | 102,249 | 1.67 mm | 219,867 |
27 Feb 24 | Ashley Cordova | Stock Options Ordinary Shares | Grant | Acquire A | No | No | 16.3 | 156,348 | 2.55 mm | 156,348 |
27 Feb 24 | Frank X Leonard | Ordinary Shares | Grant | Acquire A | No | No | 16.3 | 102,249 | 1.67 mm | 164,695 |
27 Feb 24 | Frank X Leonard | Stock Options Ordinary Shares | Grant | Acquire A | No | No | 16.3 | 156,348 | 2.55 mm | 156,348 |
27 Feb 24 | Michal Nath Puri | Ordinary Shares | Grant | Acquire A | No | No | 16.3 | 71,574 | 1.17 mm | 109,167 |
News
Peeling Back The Layers: Exploring NovoCure Through Analyst Insights
27 Mar 24
HC Wainwright & Co. Maintains Neutral on NovoCure, Raises Price Target to $24
27 Mar 24
Novocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Shows
27 Mar 24
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
27 Mar 24
Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Extension In Time To Intracranial Progression For Patients With Brain Metastases From Non-Small Cell Lung Cancer
27 Mar 24
Press releases
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
27 Mar 24
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
27 Mar 24
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
22 Feb 24
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
18 Jan 24
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
9 Jan 24